Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MACOM Technology (MTSI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

MACOM TechnologyTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

MACOM Technology vs Vertex Pharmaceuticals Incorporated — how do they compare? MACOM Technology trades at $284.04 (market cap $20.99B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.4× MACOM Technology's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, MACOM Technology nearer its low. Which is the better fit depends on your goals.

MTSIVRTX
Market Cap
$20.99B$134.06B
Sector
TechnologyHealth
52-Week High
$409.68$557.96
52-Week Low
$122.18$376.62
Enterprise Value
$20.70B$128.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MACOM Technology

No Aura AI signal available yet.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.

The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MACOM Technology

MACOM develops analog, radio frequency, microwave, and optical semiconductors. Its components are used in telecommunications, data centers, industrial systems, aerospace, and defense applications.

Read more on MTSI

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX